Premium
Paclitaxel‐Loaded PLA/PEG/Magnetite Anticancer and Hyperthermic Agent Prepared From Materials Obtained by the Ugi's Multicomponent Reaction
Author(s) -
Peña Icart Luis,
Fernandes dos Santos Edson,
Agüero Luztonó Lissette,
Zaldívar Silva Dionisio,
Andrade Leonardo,
Lopes Dias Marcos,
Trambaioli da Rocha e Lima Luis M.,
Gomes de Souza Fernando
Publication year - 2018
Publication title -
macromolecular symposia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.257
H-Index - 76
eISSN - 1521-3900
pISSN - 1022-1360
DOI - 10.1002/masy.201800094
Subject(s) - ethylene glycol , magnetite , materials science , paclitaxel , nuclear chemistry , magnetic hyperthermia , peg ratio , drug delivery , controlled release , high performance liquid chromatography , chromatography , chemistry , chemical engineering , magnetic nanoparticles , nanoparticle , nanotechnology , organic chemistry , metallurgy , cancer , medicine , finance , economics , engineering
In this study, Magnetic microspheres formed by Magnetite, Paclitaxel (PCT), poly(lactic acid) (PLA), and poly(ethylene glycol) (PEG) diblock copolymers material, synthesized by the Ugi four‐component condensation reaction (UFCC), are prepared by single emulsion and solvent evaporation procedure. Prepared PCT‐loaded magnetic microspheres (PCTMMS) are characterized by magnetic induction hyperthermia (MIH), SEM, and LDS techniques. Microencapsulation process yielded PCT encapsulation efficiency (Ee) between 70 and 80%, determined by HPLC analysis of the resulting supernatant after the microencapsulation process. A kinetic study of drug release in vitro using HPLC showed a sustained and controlled release of PCT. Also, the presence of an external magnetic field speeds up the kinetic release profile of PCT. Anticancer activity of release medium against intestine cancer cell line (Caco2) is determined using the cell viability assay. PCTMMSs are able to inhibit cancer cell growth and colony formation. The main contribution of these results is to propose a new application for UFCC in the preparation of one anticancer and hyperthermic drug delivery systems (DDS) able to improve the cancer treatment and even the welfare of the patients.